Loos M, Delforge A, Mattelaer M, Laduron C, Brassinne C, Hildebrand J, Stryckmans P
Anticancer Res. 1981;1(6):393-6.
Nocodazole, a water insoluble antimitotic drug active on L1210 leukemia was incorporated into liposomes, to investigate whether this procedure could increase cellular uptake. The effects of micronized nocodazole and liposome-entrapped nocodazole were compared on human marrow cells in vitro using a myeloid progenitor cell assay (CFU-C). The human CFU-C were sensitive to the micronized drug in a dose-related fashion. However, contrasting with a previous report on L 1210 leukemia, entrapping of nocodazole into liposomes did not increase its activity of CFU-C of either normal or leukemic subjects.
诺考达唑是一种对L1210白血病有效的水不溶性抗有丝分裂药物，将其包封于脂质体中，以研究该方法是否能增加细胞摄取。使用髓系祖细胞测定法（CFU-C）在体外比较了微粉化诺考达唑和脂质体包裹的诺考达唑对人骨髓细胞的作用。人CFU-C对微粉化药物呈剂量相关的敏感性。然而，与之前关于L1210白血病的报道相反，将诺考达唑包封于脂质体中并未增加其对正常或白血病受试者CFU-C的活性。
